GRFS vs SNY
Grifols SA and Sanofi, side by side — 10 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | GRFS | SNY |
|---|---|---|
| Revenue | €7.2B | €43.6B |
| Net income | €156.9M | €7.8B |
| Gross margin | 38.7% | 77.2% |
| Net margin | 2.2% | 17.9% |
| Return on equity | 2.8% | 10.5% |
| Diluted EPS | €0.23 | €6.37 |
| Dividend / share | — | €3.92 |
| Payout ratio | 0.6% | 61.1% |
| Free cash flow | €669.6M | — |
| Equity | €5.9B | €71.4B |
| Net debt / equity | −0.42× | 0.15× |
| Current ratio | 2.66× | 1.09× |
| Revenue CAGR 5y | 7.2% | 3.9% |
| Profit CAGR 5y | −24.2% | −8.7% |
SNY bills 6.0× the revenue of GRFS, and keeps more of each dollar of revenue as profit (17.9% against 2.2%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | GRFS | SNY |
|---|---|---|
| FY2024 | €7.2B | €41.1B |
| FY2023 | €6.6B | €37.8B |
| FY2022 | €6.1B | €37.7B |
| FY2021 | €4.9B | €37.8B |
| FY2020 | €5.3B | €36.0B |
| FY2019 | €5.1B | €36.1B |
| FY2018 | €4.5B | €34.5B |
| FY2017 | €4.3B | €35.1B |
| FY2016 | €4.0B | €33.8B |
| FY2015 | €3.9B | €34.1B |
Net income by year
Bottom line
| Fiscal year | GRFS | SNY |
|---|---|---|
| FY2024 | €156.9M | €5.6B |
| FY2023 | €42.3M | €5.4B |
| FY2022 | €185.0M | €8.4B |
| FY2021 | €188.7M | €6.2B |
| FY2020 | €618.5M | €12.3B |
| FY2019 | €625.1M | €2.8B |
| FY2018 | €596.6M | €4.3B |
| FY2017 | €662.7M | €8.4B |
| FY2016 | €545.5M | €4.7B |
| FY2015 | €532.1M | €4.3B |
Advertisement
AdSense · Rectangle 336×280